Basilea's Sales Milestones: A Major Achievement
Basilea Pharmaceutica Ltd, a leading biopharmaceutical company, has made waves recently with impressive sales figures for its flagship products, Cresemba and Zevtera. The sales of these essential medical treatments not only underscore the effectiveness of Basilea's innovations but also signal significant progress in battling severe bacterial and fungal infections across various regions.
Sales Growth Overview
In a recent announcement, Basilea revealed that the combined sales of Cresemba and Zevtera surpassed expectations in 2024, leading to milestone payments from distribution partners cumulatively amounting to approximately CHF 2.2 million. This is a testament to the growing demand and therapeutic impact of these products in the healthcare market.
Key Contributors to Sales Growth
Cresemba, the antifungal agent, achieved outstanding sales performance in Canada, courtesy of AVIR Pharma Inc. Additionally, it secured its first sales milestone in the Middle East and North Africa (MENA) region with Hikma Pharmaceuticals LLC. Meanwhile, Zevtera, the potent antibiotic, made significant strides in Europe, with milestone payments recognized from Advanz Pharma.
Market Reach and Performance
Basilea’s commercial relationships span over 100 countries, reflecting their commitment to global health. By the end of 2024, Cresemba had been marketed in more than 70 countries, while Zevtera was available in 20 countries. According to market insights, global sales of Cresemba during a recent twelve-month tracking period reached approximately USD 533 million, showcasing a remarkable 20 percent increase compared to the previous year. This achievement positions Cresemba as the leading branded antifungal treatment for invasive fungal infections worldwide.
Introduction to Cresemba
Cresemba, known scientifically as isavuconazole, is a versatile antifungal agent administered both intravenously and orally. It has received approval for treating invasive aspergillosis and invasive mucormycosis in diverse age groups in Canada and is also widely approved across the US and European markets. This broad approval highlights Cresemba's efficacy in tackling life-threatening fungal infections.
The Impact of Zevtera
Zevtera, or ceftobiprole medocaril sodium, represents a significant advancement in the antibiotic category. As an advanced generation cephalosporin, it effectively combats various Gram-positive and Gram-negative bacteria, including challenging strains like methicillin-resistant Staphylococcus aureus (MRSA). Zevtera enjoys approvals in several countries, making it a vital asset in the treatment of hospital-acquired and community-acquired bacterial pneumonia.
The Vision of Basilea
Founded in 2000, Basilea is dedicated to addressing the unmet medical needs associated with severe infections. The company's ongoing clinical efforts demonstrate their commitment to innovation, as they continue to explore new avenues in drug discovery and development. With two successful hospital brands already launched and additional assets in various stages of clinical development, the future looks bright for Basilea.
Looking to the Future
With the recent milestone payments and the evident sales growth of their products, Basilea has solidified its position within the biopharmaceutical landscape. Investors and healthcare professionals alike can be optimistic about the company’s future trajectory as they strive to enhance treatment options for patients battling severe infections globally.
Contact Information
For further queries, please reach out to the following:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd
Hegenheimermattweg 167b
4123 Allschwil, Switzerland
Phone: +41 61 606 1102
Email: media_relations@basilea.com, investor_relations@basilea.com
Frequently Asked Questions
What progress has Basilea made in 2024?
Basilea has reported significant sales growth for Cresemba and Zevtera, triggering milestone payments exceeding CHF 2.2 million.
In which regions are Cresemba and Zevtera marketed?
Cresemba is marketed in over 70 countries, while Zevtera is available in 20 countries worldwide.
What is Cresemba used for?
Cresemba is an antifungal used for treating invasive aspergillosis and invasive mucormycosis in both adult and pediatric populations.
What type of antibiotic is Zevtera?
Zevtera is an advanced generation cephalosporin antibiotic effective against a broad spectrum of bacteria, including MRSA.
How does Basilea ensure global health impact?
Basilea collaborates with distribution partners worldwide to expand the reach and accessibility of its products, ultimately striving to meet critical healthcare needs.
